{"name":"Dompé Farmaceutici S.p.A","slug":"domp-farmaceutici-spa","ticker":"","exchange":"","domain":"dompfarmaceuticispa.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"oncology","drugs":[{"name":"Fluifort® syrup","genericName":"Fluifort® syrup","slug":"fluifort-syrup","indication":"Other","status":"phase_1"},{"name":"DFL24498","genericName":"DFL24498","slug":"dfl24498","indication":"Other","status":"phase_3"},{"name":"Reparixin continuous infusion","genericName":"Reparixin continuous infusion","slug":"reparixin-continuous-infusion","indication":"Other","status":"phase_2"},{"name":"reparixin intermittent infusion","genericName":"reparixin intermittent infusion","slug":"reparixin-intermittent-infusion","indication":"Other","status":"phase_2"},{"name":"KSL 40 mg","genericName":"KSL 40 mg","slug":"ksl-40-mg","indication":"Other","status":"phase_1"},{"name":"Repertaxin","genericName":"Repertaxin","slug":"repertaxin","indication":"Other","status":"phase_2"},{"name":"rhNGF","genericName":"rhNGF","slug":"rhngf","indication":"Other","status":"phase_2"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"neuroscience","drugs":[{"name":"Ketoprofen Lysine Salt","genericName":"Ketoprofen Lysine Salt","slug":"ketoprofen-lysine-salt","indication":"Acute pain management","status":"marketed"},{"name":"OXERVATE® 0.002%","genericName":"OXERVATE® 0.002%","slug":"oxervate-0-002","indication":"Neurotrophic keratopathy (corneal ulceration and epithelial defects due to corneal nerve damage)","status":"marketed"},{"name":"Oxervate","genericName":"Oxervate","slug":"oxervate","indication":"Neurotrophic keratitis","status":"marketed"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Libexin®","genericName":"Libexin®","slug":"libexin","indication":"Dry cough and unproductive cough in various respiratory conditions","status":"phase_3"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"OKITASK®","genericName":"OKITASK®","slug":"okitask","indication":"Dry eye disease (moderate to severe)","status":"phase_3"}]}],"pipeline":[{"name":"Fluifort® syrup","genericName":"Fluifort® syrup","slug":"fluifort-syrup","phase":"phase_1","mechanism":"Carbocysteine normalizes mucus viscosity by regulating mucin production and breaking disulfide bonds in mucoproteins.","indications":[],"catalyst":""},{"name":"Libexin®","genericName":"Libexin®","slug":"libexin","phase":"phase_3","mechanism":"Libexin is a non-narcotic antitussive agent that suppresses cough by acting as a local anesthetic on the respiratory mucosa and reducing airway irritation.","indications":["Dry cough and unproductive cough in various respiratory conditions"],"catalyst":""},{"name":"DFL24498","genericName":"DFL24498","slug":"dfl24498","phase":"phase_3","mechanism":"DFL24498 is a tyrosine kinase inhibitor targeting specific oncogenic pathways in cancer cells.","indications":[],"catalyst":""},{"name":"OKITASK®","genericName":"OKITASK®","slug":"okitask","phase":"phase_3","mechanism":"OKITASK is a topical ophthalmic agent designed to promote corneal healing and reduce inflammation in dry eye disease.","indications":["Dry eye disease (moderate to severe)"],"catalyst":""},{"name":"Reparixin continuous infusion","genericName":"Reparixin continuous infusion","slug":"reparixin-continuous-infusion","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"reparixin intermittent infusion","genericName":"reparixin intermittent infusion","slug":"reparixin-intermittent-infusion","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"KSL 40 mg","genericName":"KSL 40 mg","slug":"ksl-40-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ketoprofen Lysine Salt","genericName":"Ketoprofen Lysine Salt","slug":"ketoprofen-lysine-salt","phase":"marketed","mechanism":"Ketoprofen lysine salt is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and provide analgesic, anti-inflammatory, and antipyretic effects.","indications":["Acute pain management","Postoperative pain","Migraine headache","Musculoskeletal pain and inflammation"],"catalyst":""},{"name":"OXERVATE® 0.002%","genericName":"OXERVATE® 0.002%","slug":"oxervate-0-002","phase":"marketed","mechanism":"OXERVATE contains recombinant human nerve growth factor (rhNGF) that promotes corneal nerve regeneration and healing of neurotrophic keratopathy.","indications":["Neurotrophic keratopathy (corneal ulceration and epithelial defects due to corneal nerve damage)"],"catalyst":""},{"name":"Oxervate","genericName":"Oxervate","slug":"oxervate","phase":"marketed","mechanism":"High affinity nerve growth factor receptor, Tumor necrosis factor receptor superfamily member 16","indications":["Neurotrophic keratitis"],"catalyst":""},{"name":"Repertaxin","genericName":"Repertaxin","slug":"repertaxin","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"rhNGF","genericName":"rhNGF","slug":"rhngf","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":12,"phaseCounts":{"phase_1":2,"phase_3":3,"phase_2":4,"marketed":3},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}